



Premature termination of a Clinical Trial

Full title of the clinical Trial: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study

EudraCT Number: 2021-006172-16

Sponsor: Medical University of Graz

Represented by (name): Martin Stradner, MD

Reason for premature termination of the clinical trial: Lack of funding for the analyses planned

Study results (if available): 140 subjects were recruited in the study. Booster vaccination was safe, with no SAE occurring related to vaccination. 44 participants experienced a vaccination breakthrough within 6 months after booster vaccination. None of them lead to COVID-19-related hospitalization or death. Anti-SARS-CoV-2 Spike antibodies were detected in all participants after vaccination.

Date and Signature of Sponsor representative:

3.10.2023, Martin Stradner, MD